Editas Medicine Stock Price, News & Analysis (NASDAQ:EDIT)

$24.96 -0.82 (-3.18 %)
(As of 12/11/2017 01:51 PM ET)
Previous Close$25.78
Today's Range$24.50 - $26.19
52-Week Range$13.12 - $31.81
Volume1.25 million shs
Average Volume940,629 shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta5

About Editas Medicine (NASDAQ:EDIT)

Editas Medicine logoEditas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000

Debt

Debt-to-Equity Ratio0.19%
Current Ratio10.12%
Quick Ratio10.12%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.05 million
Price / Sales181.86
Cash FlowN/A
Price / CashN/A
Book Value$3.67 per share
Price / Book6.80

Profitability

Trailing EPS($3.24)
Net Income$-97,180,000.00
Net Margins-1,127.03%
Return on Equity-70.19%
Return on Assets-37.08%

Miscellaneous

Employees89
Outstanding Shares44,080,000

Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How were Editas Medicine's earnings last quarter?

Editas Medicine Inc (NASDAQ:EDIT) posted its earnings results on Tuesday, November, 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.04. The business had revenue of $6.28 million for the quarter, compared to analysts' expectations of $2.66 million. Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. Editas Medicine's quarterly revenue was up 553.0% on a year-over-year basis. During the same period last year, the firm posted ($0.59) earnings per share. View Editas Medicine's Earnings History.

When will Editas Medicine make its next earnings announcement?

Editas Medicine is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Editas Medicine.

Where is Editas Medicine's stock going? Where will Editas Medicine's stock price be in 2017?

9 equities research analysts have issued 1-year price objectives for Editas Medicine's shares. Their forecasts range from $17.00 to $35.00. On average, they anticipate Editas Medicine's share price to reach $27.00 in the next year. View Analyst Ratings for Editas Medicine.

What are Wall Street analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:

  • 1. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (11/13/2017)
  • 2. Cann analysts commented, "Loss per share was $0.64, compared to our estimated loss of $0.67. This was the result of higher than expected Collaborative Revenue of $6.3 million compared to our estimate of $2.0 million. This was partially offset by higher than estimated operating expenses of $33.0 million, compared to our estimated $29.0 million. Higher than estimated Collaboration Revenue was primarily the result of the timing of an Allergan revenue recognition of $2.5 million, and a Juno Therapeutics revenue recognition of $3.2 million. There were no other meaningful variances in the quarter." (11/7/2017)
  • 3. Chardan Capital analysts commented, "We initiate coverage of Editas Medicine (EDIT) with a Buy rating (PT $65), on our view of the company's IP breadth and strength providing significant upside potential for shares, via both internal and partnered program opportunities. Editas is a preclinical biotech company aiming to treat various genetic conditions through the CRISPR gene editing system, in which a CRISPR guide RNA (gRNA) delivers a nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Editas' lead asset, targeting Leber's congenital amaurosis type 10 (LCA10), could be one of the first CRISPR therapies to enter the clinic. An IND filing is expected by year-end 2017." (3/27/2017)

Who are some of Editas Medicine's key competitors?

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the folowing people:

  • Katrine S. Bosley, President, Chief Executive Officer, Director (Age 49)
  • Andrew A. F. Hack, Chief Financial Officer (Age 43)
  • Charles Albright, Chief Scientific Officer (Age 59)
  • Gerald Cox, Chief Medical Officer (Age 58)
  • Andrew Hirsch, Director (Age 46)
  • Akshay K. Vaishnaw M.D., Ph.D., Director (Age 54)
  • Kevin J. Bitterman Ph.D., Independent Director (Age 40)
  • Alexis Borisy, Independent Director (Age 45)
  • Douglas G. Cole M.D., Independent Director (Age 56)

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who owns Editas Medicine stock?

Editas Medicine's stock is owned by many different of institutional and retail investors. Top institutional shareholders include American Century Companies Inc. (0.76%), Granahan Investment Management Inc. MA (0.57%), Greenwoods Asset Management Ltd (0.43%), Bank of New York Mellon Corp (0.40%), Allianz Asset Management GmbH (0.32%) and Schwab Charles Investment Management Inc. (0.28%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Gerald Frank Cox, James E Flynn, Katrine Bosley, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.

Who sold Editas Medicine stock? Who is selling Editas Medicine stock?

Editas Medicine's stock was sold by a variety of institutional investors in the last quarter, including Crestwood Advisors Group LLC, Commonwealth Equity Services Inc, California State Teachers Retirement System and TD Asset Management Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Alexandra Glucksmann, Andrew A F Hack, Katrine Bosley and Kevin Bitterman. View Insider Buying and Selling for Editas Medicine.

Who bought Editas Medicine stock? Who is buying Editas Medicine stock?

Editas Medicine's stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., Allianz Asset Management GmbH, Greenwoods Asset Management Ltd, First Midwest Bank Trust Division, GSA Capital Partners LLP, Bank of New York Mellon Corp, Trexquant Investment LP and Schwab Charles Investment Management Inc.. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and James E Flynn. View Insider Buying and Selling for Editas Medicine.

How do I buy Editas Medicine stock?

Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Editas Medicine's stock price today?

One share of Editas Medicine stock can currently be purchased for approximately $24.96.

How big of a company is Editas Medicine?

Editas Medicine has a market capitalization of $1.10 billion and generates $6.05 million in revenue each year. The company earns $-97,180,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. Editas Medicine employs 89 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]


MarketBeat Community Rating for Editas Medicine (EDIT)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  240
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Editas Medicine (NASDAQ:EDIT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.442.442.502.67
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.00$27.00$26.75$33.75
Price Target Upside: 17.04% upside17.04% upside35.86% upside63.12% upside

Editas Medicine (NASDAQ:EDIT) Consensus Price Target History

Price Target History for Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ:EDIT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017CannReiterated RatingHoldN/AView Rating Details
11/7/2017CowenReiterated RatingBuyN/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 -> $28.00N/AView Rating Details
9/6/2017BarclaysInitiated CoverageOverweight$19.69 -> $28.00MediumView Rating Details
8/9/2017J P Morgan Chase & CoSet Price TargetHold$27.00HighView Rating Details
7/18/2017OppenheimerMarket PerformN/AView Rating Details
7/13/2017SunTrust BanksInitiated CoverageHold -> Hold$17.00HighView Rating Details
3/27/2017Chardan CapitalInitiated CoverageBuy -> BuyHighView Rating Details
2/15/2017Jefferies GroupReiterated RatingBuy$35.00N/AView Rating Details
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Editas Medicine (NASDAQ:EDIT) Earnings History and Estimates Chart

Earnings by Quarter for Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ EDIT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($0.75)N/AView Earnings Details
11/7/2017Q3 2017($0.60)($0.64)$2.66 million$6.28 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.64)($0.65)$2.20 million$3.10 millionViewListenView Earnings Details
5/15/2017Q1 2017($0.62)($0.85)$1.00 million$0.68 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.62)($1.10)$1.11 million$0.90 millionViewListenView Earnings Details
11/7/2016Q3($0.64)($0.59)$1.00 million$1.00 millionViewListenView Earnings Details
8/9/2016Q2($0.54)($0.54)$3.52 million$3.39 millionViewListenView Earnings Details
5/16/2016Q116($0.23)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details
3/30/2016Q4($0.52)($4.05)$0.79 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Editas Medicine (NASDAQ:EDIT) Earnings Estimates

2017 EPS Consensus Estimate: ($3.02)
2018 EPS Consensus Estimate: ($3.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.66)($0.66)($0.66)
Q2 20171($0.70)($0.70)($0.70)
Q3 20173($0.75)($0.67)($0.72)
Q4 20173($1.36)($0.69)($0.94)
Q1 20182($0.96)($0.70)($0.83)
Q2 20182($0.84)($0.72)($0.78)
Q3 20182($0.97)($0.74)($0.86)
Q4 20182($1.56)($0.76)($1.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Editas Medicine (NASDAQ:EDIT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Editas Medicine (NASDAQ EDIT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.40%
Institutional Ownership Percentage: 70.12%
Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ EDIT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Katrine BosleyInsiderSell8,333$29.58$246,490.14View SEC Filing  
11/20/2017Andrew A F HackCFOSell5,000$25.35$126,750.00View SEC Filing  
11/17/2017Andrew A F HackCFOSell5,000$24.81$124,050.00View SEC Filing  
11/1/2017Katrine BosleyInsiderSell8,333$23.64$196,992.12View SEC Filing  
10/2/2017Katrine BosleyInsiderSell8,333$24.78$206,491.74View SEC Filing  
9/5/2017Katrine BosleyInsiderSell16,666$20.33$338,819.78View SEC Filing  
9/1/2017Katrine BosleyCEOSell10,000$20.42$204,200.00View SEC Filing  
8/11/2017Katrine BosleyInsiderSell16,666$20.02$333,653.32View SEC Filing  
6/2/2017Boris NikolicDirectorBuy35,000$14.07$492,450.00View SEC Filing  
6/2/2017Gerald Frank CoxInsiderBuy4,000$14.15$56,600.00View SEC Filing  
5/22/2017Kevin BittermanDirectorSell1,000,000$17.00$17,000,000.00View SEC Filing  
3/15/2017Alexandra GlucksmannCOOSell1,000$26.41$26,410.00View SEC Filing  
2/15/2017Alexandra GlucksmannCOOSell6,000$20.58$123,480.00View SEC Filing  
2/15/2017Andrew A F HackCFOSell3,000$19.20$57,600.00View SEC Filing  
1/11/2017Andrew A F HackCFOSell15,000$19.20$288,000.00View SEC Filing  
12/7/2016Polaris Venture Management Co.Major ShareholderSell75,000$15.82$1,186,500.00View SEC Filing  
12/6/2016Kevin BittermanDirectorSell130,000$15.79$2,052,700.00View SEC Filing  
11/23/2016Kevin BittermanDirectorSell21,480$15.71$337,450.80View SEC Filing  
11/22/2016Polaris Venture Management Co.Major ShareholderSell12,819$15.77$202,155.63View SEC Filing  
11/15/2016Kevin BittermanDirectorSell88,900$16.96$1,507,744.00View SEC Filing  
9/8/2016Polaris Venture Management Co.Major ShareholderSell500,000$16.80$8,400,000.00View SEC Filing  
9/6/2016Kevin P. StarrMajor ShareholderSell5,890$15.90$93,651.00View SEC Filing  
8/23/2016Alexandra GlucksmannCOOSell1,000$20.00$20,000.00View SEC Filing  
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Editas Medicine (NASDAQ EDIT) News Headlines

Source:
DateHeadline
BidaskClub Lowers Editas Medicine (EDIT) to HoldBidaskClub Lowers Editas Medicine (EDIT) to Hold
www.americanbankingnews.com - December 9 at 6:32 PM
Editas Medicine Inc (EDIT) Receives Consensus Recommendation of "Hold" from BrokeragesEditas Medicine Inc (EDIT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 9 at 1:48 AM
Zacks: Analysts Anticipate Editas Medicine Inc (EDIT) Will Announce Quarterly Sales of $3.33 MillionZacks: Analysts Anticipate Editas Medicine Inc (EDIT) Will Announce Quarterly Sales of $3.33 Million
www.americanbankingnews.com - December 8 at 1:54 PM
Editas Medicine, Inc., Announces Offering of Common Stock - GlobeNewswire (press release)Editas Medicine, Inc., Announces Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - December 6 at 5:11 PM
Heres Why Editas Medicine Inc. Stock Is Slipping Today - Motley FoolHere's Why Editas Medicine Inc. Stock Is Slipping Today - Motley Fool
www.fool.com - December 6 at 5:11 PM
Here's Why Editas Medicine Inc. Stock Is Slipping TodayHere's Why Editas Medicine Inc. Stock Is Slipping Today
finance.yahoo.com - December 6 at 5:11 PM
Heres Why Editas Medicine Inc. Stock Is Slipping TodayHere's Why Editas Medicine Inc. Stock Is Slipping Today
www.fool.com - December 6 at 1:34 PM
Editas Medicine (EDIT) Prices $50M Offering of Common StockEditas Medicine (EDIT) Prices $50M Offering of Common Stock
www.streetinsider.com - December 6 at 9:52 AM
Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common StockEditas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock
finance.yahoo.com - December 6 at 9:52 AM
Contrasting Editas Medicine (EDIT) and Organovo (ONVO)Contrasting Editas Medicine (EDIT) and Organovo (ONVO)
www.americanbankingnews.com - December 6 at 1:28 AM
BRIEF-Editas Medicine Announces Offering Of Common StockBRIEF-Editas Medicine Announces Offering Of Common Stock
www.reuters.com - December 5 at 5:06 PM
Editas Medicine, Inc., Announces Offering of Common StockEditas Medicine, Inc., Announces Offering of Common Stock
finance.yahoo.com - December 5 at 5:06 PM
Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT DeficiencyAdverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT Deficiency
globenewswire.com - December 5 at 10:23 AM
Editas Medicine Inc (EDIT) Insider Katrine Bosley Sells 8,333 SharesEditas Medicine Inc (EDIT) Insider Katrine Bosley Sells 8,333 Shares
www.americanbankingnews.com - December 5 at 8:30 AM
Editas Medicine (EDIT) Downgraded to Sell at ValuEngineEditas Medicine (EDIT) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 3:48 PM
Here's Why Sangamo Therapeutics Rose as Much as 14.9% ThursdayHere's Why Sangamo Therapeutics Rose as Much as 14.9% Thursday
finance.yahoo.com - November 30 at 5:06 PM
Commit To Purchase Editas Medicine At $15, Earn 9.7% Using OptionsCommit To Purchase Editas Medicine At $15, Earn 9.7% Using Options
www.nasdaq.com - November 28 at 5:10 PM
Editas Medicine Target of Unusually Large Options Trading (EDIT)Editas Medicine Target of Unusually Large Options Trading (EDIT)
www.americanbankingnews.com - November 27 at 2:52 AM
Disruptor Alert: These 5 Companies Are Changing HealthcareDisruptor Alert: These 5 Companies Are Changing Healthcare
finance.yahoo.com - November 22 at 4:29 AM
Editas Medicine, Inc. (EDIT) CFO Sells $124,050.00 in StockEditas Medicine, Inc. (EDIT) CFO Sells $124,050.00 in Stock
www.americanbankingnews.com - November 21 at 4:40 PM
Insider Selling: Editas Medicine, Inc. (EDIT) CFO Sells 5,000 Shares of StockInsider Selling: Editas Medicine, Inc. (EDIT) CFO Sells 5,000 Shares of Stock
www.americanbankingnews.com - November 21 at 4:20 PM
$3.33 Million in Sales Expected for Editas Medicine, Inc. (EDIT) This Quarter$3.33 Million in Sales Expected for Editas Medicine, Inc. (EDIT) This Quarter
www.americanbankingnews.com - November 20 at 2:48 PM
Editas Medicine, Inc. (EDIT) Expected to Post Earnings of -$0.79 Per ShareEditas Medicine, Inc. (EDIT) Expected to Post Earnings of -$0.79 Per Share
www.americanbankingnews.com - November 18 at 8:06 AM
EDIT: Insiders Vs. ShortsEDIT: Insiders Vs. Shorts
www.thestreet.com - November 16 at 6:45 PM
Head-To-Head Survey: Editas Medicine (EDIT) vs. Its PeersHead-To-Head Survey: Editas Medicine (EDIT) vs. Its Peers
www.americanbankingnews.com - November 16 at 5:20 AM
Editas Medicine, Inc. (EDIT) Given Consensus Rating of "Hold" by AnalystsEditas Medicine, Inc. (EDIT) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - November 14 at 1:50 AM
Zacks Investment Research Downgrades Editas Medicine, Inc. (EDIT) to HoldZacks Investment Research Downgrades Editas Medicine, Inc. (EDIT) to Hold
www.americanbankingnews.com - November 13 at 11:46 PM
Biotech Stocks on Investors Radar -- Endocyte, Editas Medicine ... - PR Newswire (press release)Biotech Stocks on Investors' Radar -- Endocyte, Editas Medicine ... - PR Newswire (press release)
www.prnewswire.com - November 13 at 11:46 PM
Editas Medicine, Inc. (EDIT) Lifted to "Buy" at Zacks Investment ResearchEditas Medicine, Inc. (EDIT) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 10 at 9:58 PM
Short Interest Makes 10.3% Move For EDITShort Interest Makes 10.3% Move For EDIT
www.thestreet.com - November 10 at 6:57 PM
Barclays: Editas Medicine On Track To File New Drug App Next Year - BenzingaBarclays: Editas Medicine On Track To File New Drug App Next Year - Benzinga
www.benzinga.com - November 10 at 8:05 AM
Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : November 9, 2017Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : November 9, 2017
finance.yahoo.com - November 10 at 8:05 AM
Editas Medicine Keeps Moving ForwardEditas Medicine Keeps Moving Forward
finance.yahoo.com - November 10 at 8:05 AM
FY2017 Earnings Forecast for Editas Medicine, Inc. (EDIT) Issued By Oppenheimer HoldingsFY2017 Earnings Forecast for Editas Medicine, Inc. (EDIT) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 10 at 7:47 AM
FY2017 Earnings Forecast for Editas Medicine, Inc. (EDIT) Issued By SunTrust BanksFY2017 Earnings Forecast for Editas Medicine, Inc. (EDIT) Issued By SunTrust Banks
www.americanbankingnews.com - November 10 at 7:47 AM
BRIEF-Editas Medicine announces Q3 loss per share $0.64BRIEF-Editas Medicine announces Q3 loss per share $0.64
www.reuters.com - November 9 at 1:35 AM
What Investors Should Know About Editas Medicine Inc’s (EDIT) Financial StrengthWhat Investors Should Know About Editas Medicine Inc’s (EDIT) Financial Strength
finance.yahoo.com - November 9 at 1:35 AM
Here's Why Editas Medicine Collapsed at Market Open TodayHere's Why Editas Medicine Collapsed at Market Open Today
finance.yahoo.com - November 9 at 1:35 AM
Barclays: Editas Medicine On Track To File New Drug App Next YearBarclays: Editas Medicine On Track To File New Drug App Next Year
finance.yahoo.com - November 9 at 1:35 AM
Head to Head Survey: Editas Medicine (EDIT) & CytRx Corporation (CYTR)Head to Head Survey: Editas Medicine (EDIT) & CytRx Corporation (CYTR)
www.americanbankingnews.com - November 8 at 5:31 PM
BRIEF-Editas Medicine announces Q3 loss per share $0.64 - ReutersBRIEF-Editas Medicine announces Q3 loss per share $0.64 - Reuters
www.reuters.com - November 8 at 5:38 AM
Editas Medicine Announces Third Quarter 2017 Results and Update - GlobeNewswire (press release)Editas Medicine Announces Third Quarter 2017 Results and Update - GlobeNewswire (press release)
globenewswire.com - November 8 at 5:38 AM
Editas Medicine Announces Third Quarter 2017 Results and UpdateEditas Medicine Announces Third Quarter 2017 Results and Update
finance.yahoo.com - November 8 at 5:38 AM
Editas reports 3Q lossEditas reports 3Q loss
finance.yahoo.com - November 8 at 5:38 AM
Edited Transcript of EDIT earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of EDIT earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 8 at 5:38 AM
Cann Reaffirms "Hold" Rating for Editas Medicine, Inc. (EDIT)Cann Reaffirms "Hold" Rating for Editas Medicine, Inc. (EDIT)
www.americanbankingnews.com - November 7 at 11:51 PM
Cowen and Company Reaffirms "Buy" Rating for Editas Medicine, Inc. (EDIT)Cowen and Company Reaffirms "Buy" Rating for Editas Medicine, Inc. (EDIT)
www.americanbankingnews.com - November 7 at 7:46 PM
Editas Medicine, Inc. (EDIT) Issues  Earnings ResultsEditas Medicine, Inc. (EDIT) Issues Earnings Results
www.americanbankingnews.com - November 7 at 5:27 PM
Whats in the Cards for Adverum (ADVM) This Earnings Season?What's in the Cards for Adverum (ADVM) This Earnings Season?
finance.yahoo.com - November 4 at 8:16 PM
Editas Medicine, Inc. (EDIT) Insider Sells $196,992.12 in StockEditas Medicine, Inc. (EDIT) Insider Sells $196,992.12 in Stock
www.americanbankingnews.com - November 3 at 6:31 PM

SEC Filings

Editas Medicine (NASDAQ:EDIT) SEC Filings

DateFilerForm TypeView
12/07/2017
3:23 PM
Editas Medicine (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing
12/07/2017
3:19 PM
Editas Medicine (Filer)
Form 424B5
View Filing
12/05/2017
3:19 PM
Editas Medicine (Filer)
Form 424B5
View Filing
12/05/2017
5:08 AM
Bosley Katrine (Reporting)
Editas Medicine (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Editas Medicine (NASDAQ:EDIT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Editas Medicine (NASDAQ EDIT) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.